MEDIQON Group AG (CHG) AI Stock Analysis

1 Followers

MEDIQON Group AG

(XETRA:CHG)

Select Model

Rating:43Neutral

Price Target:EUR 45.00▼(-3.54% Downside)

Action:reiterated

Date:10/01/26

The score is pressured primarily by weak financial performance—especially the 2025 profitability collapse and sharply higher debt—despite continued strong revenue growth and positive free cash flow. Technical indicators also point to a bearish trend, with oversold signals not yet supported by improving momentum. Valuation is constrained by losses (negative P/E) and no provided dividend yield.

Positive Factors

Strong Revenue GrowthRapid revenue expansion demonstrates strong commercial traction and increasing scale across the company’s healthcare and life sciences activities. If retained, this growth can broaden market reach and create operating leverage, although profitability must improve for the expansion to translate into durable shareholder value.

Negative Factors

Severe Profitability CollapseThe shift from a more normal gross profit level in 2024 to negative gross profit, combined with very large operating and net losses, indicates that revenue growth is not currently converting into earnings. Persistent losses could weaken retained capital and constrain investment if the cost structure does not recover.

MEDIQON Group AG (CHG) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.11B
Dividend Yield: ―
Average Volume (3M): 25.63K
Price to Earnings (P/E): -32.0
Beta (1Y): 0.27
Revenue Growth: 63.32%
EPS Growth: -47.16%
Country: Germany
Employees: 1,300
Sector: Technology
Sector Strength: 61
Industry: Software - Application

MEDIQON Group AG Business Overview & Revenue Model

Company Description

CHAPTERS Group AG, headquartered in Hamburg, Germany, was established in 1998 and rebranded from MEDIQON Group AG in July 2023. The company delivers a broad spectrum of software solutions across the DACH region, catering to numerous industries and ap...

MEDIQON Group AG Financial Statement Overview

Summary

Strong revenue growth (2025 revenue up ~37%) is outweighed by a sharp profitability breakdown (negative gross profit, ~-50m EBIT, ~-30m net loss) and a large jump in leverage (debt ~248m vs ~74m in 2024). Positive operating cash flow (~8.7m) and consistently positive free cash flow provide an important offset but do not fully neutralize earnings and balance-sheet risk.

Income Statement

34Negative

Balance Sheet

46Neutral

Cash Flow

57Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2021	Dec 2021
Income Statement
Total Revenue	214.95M	180.80M	110.67M	70.77M	28.66M	42.07M
Gross Profit	-5.09M	-12.21M	47.02M	8.38M	12.26M	6.84M
EBITDA	16.44M	-2.40M	16.35M	16.14M	7.16M	4.82M
Net Income	-34.72M	-29.65M	-11.47M	-4.08M	-2.27M	-5.88M
Balance Sheet
Total Assets	671.97M	665.02M	353.74M	223.95M	103.55M	169.28M
Cash, Cash Equivalents and Short-Term Investments	115.41M	106.74M	58.51M	50.84M	11.09M	26.28M
Total Debt	265.58M	247.94M	73.60M	69.35M	51.70M	62.09M
Total Liabilities	389.28M	351.45M	128.75M	99.87M	61.71M	77.11M
Stockholders Equity	203.11M	223.87M	224.99M	126.06M	42.57M	93.76M
Cash Flow
Free Cash Flow	6.92M	7.02M	6.96M	3.81M	1.15M	3.67M
Operating Cash Flow	8.91M	8.68M	11.47M	7.37M	2.87M	5.69M
Investing Cash Flow	-49.57M	-103.89M	-98.82M	-36.34M	-47.40M	-53.21M
Financing Cash Flow	86.39M	134.24M	89.00M	48.15M	47.06M	58.78M

MEDIQON Group AG Technical Analysis

Technical Analysis SentimentPositive

Last Price46.65

Price Trends

50DMA44.18Positive

100DMA43.14Positive

200DMA37.09Positive

Market Momentum

MACD0.84Positive

RSI54.05Neutral

STOCH70.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Positive. The current price of 46.65 is above the 20-day moving average (MA) of 46.27, above the 50-day MA of 44.18, and above the 200-day MA of 37.09, indicating a bullish trend. The MACD of 0.84 indicates Positive momentum. The RSI at 54.05 is Neutral, neither overbought nor oversold. The STOCH value of 70.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:CHG.

MEDIQON Group AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

DE:CHG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:OBS	78Outperform	EUR 44.51M	11.80	10.52%	2.12%	0.88%	9.19%
DE:ADN1	62Neutral	EUR 447.84M	28.48	9.65%	0.96%	12.73%	51.34%
Sector *	61Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
DE:BC8	60Neutral	EUR 4.27B	17.49	12.00%	2.04%	7.74%	14.82%
DE:A1OS	50Neutral	EUR 386.60M	-38.71	-8.99%	1.54%	-1.94%	-161.38%
DE:CHG	43Neutral	EUR 1.20B	-31.95	-16.26%	―	63.32%	-47.16%

* Technology Sector Average

Performance Comparison

DE:CHG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CHG	MEDIQON Group AG	46.65	10.55	29.22%
DE:ADN1	adesso AG	80.90	-12.57	-13.45%
DE:A1OS	All For One Group Se	77.80	38.19	96.40%
DE:BC8	Bechtle Aktiengesellschaft	34.28	0.18	0.52%
DE:OBS	ORBIS AG	4.72	-1.21	-20.39%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

MEDIQON Group AG AI Stock Analysis